Equities

Nurix Therapeutics Inc

NRIX:NMQ

Nurix Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)27.03
  • Today's Change-1.11 / -3.94%
  • Shares traded635.81k
  • 1 Year change+412.90%
  • Beta2.2101
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Nov 30 2023202320222021
ASSETS
Cash And Short Term Investments288309295
Total Receivables, Net--06.20
Total Inventory------
Prepaid expenses7.609.319.19
Other current assets, total----0.29
Total current assets296318311
Property, plant & equipment, net483025
Goodwill, net------
Intangibles, net------
Long term investments7.4264137
Note receivable - long term------
Other long term assets3.824.022.83
Total assets356417477
LIABILITIES
Accounts payable6.405.066.65
Accrued expenses322818
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total483841
Total current liabilities877166
Total long term debt000
Total debt000
Deferred income tax------
Minority interest------
Other liabilities, total684268
Total liabilities155113134
SHAREHOLDERS EQUITY
Common stock0.050.050.05
Additional paid-in capital746709564
Retained earnings (accumulated deficit)(545)(401)(221)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(0.66)(4.32)(0.61)
Total equity200304342
Total liabilities & shareholders' equity356417477
Total common shares outstanding494745
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.